ABVC - Rasio utang marang kapitalisasi buku ABVC BioPharma Inc.

Logo grafis ABVC BioPharma Inc. (ABVC)

ABVC BioPharma (ABVC) total debt-to-equity ratio demonstrates volatility in asset structure, with the metric reaching 0.26. This trend reflects bets on plant-based treatments for depression and ADHD. Independent researchers with transparent career tracks are driving this development. Meanwhile, modern extraction capacities consistently ensure the production of drugs for ongoing clinical trials.

ABVC (ABVC BioPharma, Inc) riwayat Utang marang nilai buku saka 04.07.2022 nganti 26.10.2026
Barang utama ABVC BioPharma Inc

Capital serves as a filter separating the fundamental value of a business from market speculation. The ultra-lean model of ABVC BioPharma, utilizing outsourcing via CROs, minimizes capital expenditures on infrastructure. This chart of the company's debt relative to its book capitalization measures the assets' dependence on borrowed funds. A decrease in this ratio confirms the strengthening of the financial base. Low debt leverage guarantees the company's resilience to external shocks.

Pesaing ABVC BioPharma

Utang-utang marang kapitalisasi buku HLN (Haleon plc)|kenvue.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Verona Pharma (VRNA)|MENS: Rasio utang marang aset resik|LGND (Ligand Pharma) - Rasio utang marang kapitalisasi buku|Amneal Corp (AMRX) - Utang marang nilai buku|PRGO (Perrigo Company plc) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku alvotech.com (ALVO)|Liquidia (LQDA) - Utang marang nilai buku|Rasio utang marang aset resik GLPG (Galapagos N.V.)|ANIP: Rasio utang marang kapitalisasi buku|MNKD - Utang-utang marang nilai buku|Utang marang nilai buku Amphastar Pharmaceuticals AMPH|PCRX - Utang marang modal buku|Utang-utang marang kapitalisasi buku ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku AQST (Aquestive Pharma)|Utang-utang marang nilai buku SCPH|Tectonic Therapeutic, Inc. (TECX) - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik tonixpharma.com (TNXP)|Utang-utang marang kapitalisasi buku SXTC (China SXT Pharmaceuticals, Inc.)|Utang-utang marang kapitalisasi buku Eupraxia Pharmaceuticals, Inc. EPRX|BHST - Utang-utang marang kapitalisasi buku|Invizyne (EXOZ) - Rasio utang marang kapitalisasi buku|oramed.com (ORMP) - Utang marang nilai buku|Entera Bio (ENTX) - Rasio utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku HYFT|Utang marang nilai buku Cumberland Pharmaceuticals Inc (CPIX)|Quantum BioPharma Limited (QNTM) - Utang marang nilai buku|Rasio utang marang aset resik FibroGen Corporation (FGEN)|Utang-utang marang kapitalisasi buku Telomir Pharmaceuticals TELO|Rasio utang marang kapitalisasi buku Rani Therapeutics Holdings RANI|Utang-utang marang kapitalisasi buku SNYR (Synergy CHC Corporation)|RLYB: Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku LEXX|PULM (Pulmatrix Corporation) - Utang-utang marang nilai buku|Rasio utang marang kapitalisasi buku Pheton Holdings Limited PTHL|Rasio utang-utang marang kapitalisasi buku Aptorum|Lyra Therapeutics (LYRA) - Utang-utang marang kapitalisasi buku|Rasio utang marang aset resik Impact BioMedical, Inc. (IBO)|Utang-utang marang kapitalisasi buku TNFA (TNF Pharmaceuticals, Inc.)|cbdMD Inc. - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku PainReform Ltd. (PRFX)|CYTO: Rasio utang marang aset resik|LIPO (Lipella Pharmaceuticals, Inc.) - Rasio utang marang kapitalisasi buku|OptiNose Inc (OPTN) - Utang marang nilai buku|PIRS (Pieris) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku Procaps Group Corp|Utang-utang marang kapitalisasi buku PTPI|Utang-utang marang kapitalisasi buku qlsyy.net (QLI)|Utang-utang marang kapitalisasi buku ACELYRIN SLRN|TFFP - Rasio utang marang kapitalisasi buku